IDOXIFENE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C28H30INO
Molecular Weight	523.4484
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC\C(=C(/C1=CC=C(I)C=C1)C2=CC=C(OCCN3CCCC3)C=C2)C4=CC=CC=C4

InChI

InChIKey=JJKOTMDDZAJTGQ-DQSJHHFOSA-N

InChI=1S/C28H30INO/c1-2-27(22-8-4-3-5-9-22)28(23-10-14-25(29)15-11-23)24-12-16-26(17-13-24)31-21-20-30-18-6-7-19-30/h3-5,8-17H,2,6-7,18-21H2,1H3/b28-27-

HIDE SMILES / InChI

Molecular Formula	C28H30INO
Molecular Weight	523.4484
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14722733 | https://www.ncbi.nlm.nih.gov/pubmed/11832257 | https://adisinsight.springer.com/drugs/800003448

Idoxifene (also known as CB 7432), a novel selective estrogen receptor modulator, is originally discovered at the CRC Centre for Cancer Therapeutics, Institute. This drug participated in clinical trials phase II in patients with locally advanced/metastatic breast cancer resistant to tamoxifen. In addition, in phase III in postmenopausal women after one year of idoxifene treatment. However, both studies were discontinued because of insufficient effectiveness.

Originator

Approval Year

PubMed

Title	Date	PubMed
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods.	2006-11	16497524
Inhibitory effects of idoxifene on hepatic fibrosis in rats.	2005-05	15842777
Antioxidant and antiapoptotic activities of idoxifene and estradiol in hepatic fibrosis in rats.	2004-01-02	14659978
Comparative analyses of mechanistic differences among antiestrogens.	1999-12	10579349
Structure-activity relationships for triphenylethylene antiestrogens on hepatic phase-I and phase-II enzyme expression.	1998-08-01	9744569

Patents

Sample Use Guides

In Vivo Use Guide

Of 47 patients eligible for response (25 idoxifene, 22 tamoxifen), two partial responses and two disease stabilizations (SD) for >6 months were seen with idoxifene (overall clinical benefit rate 16%, 95% CI 4.5-36.1%).

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:04:45 GMT 2025` Edited by `admin` on `Wed Apr 02 07:04:45 GMT 2025`
Record UNII	456UXE9867
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CB-7432

Preferred Name

English

IDOXIFENE

Official Name

English

IDOXIFENE [MART.]

Common Name

English

IDOXIFENE [USAN]

Common Name

English

CB7432

Code

English

SB-223030

Code

English

PYRROLIDINE, 1-(2-(4-(1-(4-IODOPHENYL)-2-PHENYL-1-BUTENYL)PHENOXY)ETHYL-, (E)-

Common Name

English

SB223030

Code

English

IDOXIFENE [MI]

Common Name

English

idoxifene [INN]

Common Name

English

1-(2-(P-((E)-.BETA.-ETHYL-.ALPHA.-(P-IODOPHENYL)STYRYL)PHENOXY)ETHYL)PYRROLIDINE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1821